Home Cart 0 Sign in  

[ CAS No. 51336-94-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 51336-94-8
Chemical Structure| 51336-94-8
Structure of 51336-94-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 51336-94-8 ]

Related Doc. of [ 51336-94-8 ]

Alternatived Products of [ 51336-94-8 ]

Product Details of [ 51336-94-8 ]

CAS No. :51336-94-8 MDL No. :MFCD00013252
Formula : C8H5ClF2O Boiling Point : -
Linear Structure Formula :- InChI Key :UENGBOCGGKLVJJ-UHFFFAOYSA-N
M.W : 190.57 Pubchem ID :588083
Synonyms :

Calculated chemistry of [ 51336-94-8 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.12
Num. rotatable bonds : 2
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 41.35
TPSA : 17.07 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.74 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.45
Log Po/w (XLOGP3) : 2.43
Log Po/w (WLOGP) : 3.23
Log Po/w (MLOGP) : 2.94
Log Po/w (SILICOS-IT) : 3.51
Consensus Log Po/w : 2.71

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.79
Solubility : 0.309 mg/ml ; 0.00162 mol/l
Class : Soluble
Log S (Ali) : -2.43
Solubility : 0.706 mg/ml ; 0.0037 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.93
Solubility : 0.0225 mg/ml ; 0.000118 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.41

Safety of [ 51336-94-8 ]

Signal Word:Danger Class:8
Precautionary Statements:P280-P305+P351+P338-P310 UN#:3261
Hazard Statements:H314 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 51336-94-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 51336-94-8 ]
  • Downstream synthetic route of [ 51336-94-8 ]

[ 51336-94-8 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 372-18-9 ]
  • [ 79-04-9 ]
  • [ 51336-94-8 ]
YieldReaction ConditionsOperation in experiment
89.3%
Stage #1: at 30 - 35℃; for 0.5 h;
Stage #2: at 30 - 55℃; for 5 h;
In the equipped with a thermometer, constant pressure funnel, the reflux condensation tube (with drying tube) of 250 ml of four flasks, adding inter-fluorobenzene (0.1 µM, 14 . 7g), three aluminum chloride (0.17 µM, 22 . 7g), the mixture in the 30 - 35 °C stirring 0.5h after, instillment chlorine acetyl chloride (0.12 µM, 13 . 56g), to maintain the reaction temperature. After dropping, the elevated temperature to 50 - 55 °C, continuing to stir, until no hydrogen chloride gas generation, about reaction 5h. Which is equipped with a reaction mixture in the flask is put into the ice water bath, so that the reactant temperature to 5 °C following, dropping 3 mol/L hydrochloric acid 20 ml acid hydrolysis, control drop acceleration the mixture temperature is maintained large. After the acid mixture is poured into the beaker, adding distilled water, precipitated solid, the decompression, drying, to obtain light yellow powdery solid 16.9g, yield 89.3percent. The light yellow powdery solid n-hexane recrystallization to obtain a bright yellow crystal.
88.2% at 20 - 45℃; for 5 h; Anhydrous aluminum trichloride 200 g (1.494 mol) and m-difluorobenzene 150 g (1.30 mol)Placed in 1000mL three-necked flask, stirring at room temperature, slowly dropping chloroacetyl chloride 150 g (1.30 mol)After completion of the dropwise addition, stirring was continued for 30 minutes at room temperature, and the temperature was gradually raised to 45 ° C.Stirring was continued at this temperature for 4.5 hours. The reaction solution was poured into ice water as usual to precipitate a solid,Filtration; filtrate with dichloromethane 800 mL in two extraction, combined dichloromethane extract, washed to neutral,Dried over anhydrous sodium sulfate, filtered and the solvent recovered to give a solid, iltered and the solid was recovered solvent, the resulting combined solid was recrystallized from ethanol twice to give 2-chloro-2 ',4 '-difluoroacetophenone 215 g, yield 88.2percent.
84.5%
Stage #1: With aluminum (III) chloride In dichloromethane at 0 - 20℃; for 1 h;
Stage #2: at 0 - 20℃; for 2 h;
To a stirred solution of A1C13 (14.8 g, 131.4 mmol) in DCM (100 mL) was added 2-chloroacetyl chloride (23.3 g, 175.2 mmol) at 0C and stirred at RT for 1H. To the resulting reaction mixture, a solution of 1,3-difluorobenzene (GI, 10.0 g, 87.6 mmol) in DCM (20 mL) was added dropwise at 0C and stirred at RT for 2 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with IN HCl solution, neutralized with 2N NaOH solution and extracted with DCM. The combined organic layer was washed with brine, dried over anhydrous Na2S04 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using 10percent EtOAc/hexane to afford compound GJ (14.1 g, 84.5percent) as an off-white solid. 1H NMR (400 MHz, CDC13): _ 8.08-8.02 (m, 1H), 7.06-7.01 (m, 1H), 6.96- 6.91 (m, 1H), 4.71 (s, 2H).
75%
Stage #1: With aluminum (III) chloride In 1,2-dichloro-ethane at 25 - 30℃; for 0.5 h;
Stage #2: at 0 - 30℃; for 5.5 - 8 h;
[00062] Into the solution of 1,3-difluorobenzene in 1,2-dicholoroethane (DCE) was added anhydrous aluminium chloride (1.2 molar equivalent of 1,3-difluorobenzene) at 25-30° C. and stirred for 30 minutes. The reaction mixture was then cooled to 0° C. and chloroacetyl chloride (1.1 molar equivalent of 1,3-difluorobenzene), in DCE, was then added into it over a period of 30-60 min keeping the reaction temperature below 20° C. After the addition was over, the reaction mixture was stirred at 25-30° C. for 5-7 hours. The reaction mixture was then diluted with DCE and poured into dil. hydrochloric acid (5percent) at 0-5° C. The mixture was then extracted with DCE. The combined organic layer was washed successively with 5percent aq. sodium bicarbonate solution and water. Evaporating DCE from the organic layer under reduced pressure gave an oil which on triturating with n-Hexane gave the title compound as white crystalline material (Yield 75percent of theory).

Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2003, vol. 42, # 2, p. 372 - 381
[2] Tetrahedron Asymmetry, 2010, vol. 21, # 13-14, p. 1649 - 1665
[3] Patent: CN106187924, 2016, A, . Location in patent: Paragraph 0026; 0027
[4] Patent: CN102796080, 2016, B, . Location in patent: Paragraph 0040-0042
[5] Journal of Organic Chemistry, 1995, vol. 60, # 10, p. 3000 - 3012
[6] European Journal of Medicinal Chemistry, 2009, vol. 44, # 5, p. 1913 - 1920
[7] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 6, p. 1811 - 1814
[8] Chemical Biology and Drug Design, 2012, vol. 80, # 3, p. 382 - 387
[9] Archives of Pharmacal Research, 2013, vol. 36, # 10, p. 1215 - 1222
[10] Chinese Chemical Letters, 2013, vol. 24, # 3, p. 219 - 222
[11] Patent: WO2018/165520, 2018, A1, . Location in patent: Page/Page column 209
[12] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2959 - 2962
[13] European Journal of Medicinal Chemistry, 2004, vol. 39, # 7, p. 579 - 592
[14] European Journal of Medicinal Chemistry, 2010, vol. 45, # 10, p. 4435 - 4445
[15] Chinese Chemical Letters, 2011, vol. 22, # 5, p. 519 - 522
[16] Archives of Pharmacal Research, 2011, vol. 34, # 10, p. 1649 - 1656
[17] Archives of Pharmacal Research, 2012, vol. 35, # 11, p. 1895 - 1901
[18] MedChemComm, 2013, vol. 4, # 4, p. 704 - 708
[19] RSC Advances, 2013, vol. 3, # 32, p. 13486 - 13490
[20] Patent: US6670363, 2003, B1, . Location in patent: Page column 30-31
[21] Patent: US5047548, 1991, A,
[22] Patent: US4661507, 1987, A,
[23] Patent: US4503063, 1985, A,
[24] Patent: US4507484, 1985, A,
[25] Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 22, p. 4964 - 4969
[26] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 21, p. 7146 - 7153
[27] European Journal of Medicinal Chemistry, 2009, vol. 44, # 10, p. 4218 - 4226
[28] Archiv der Pharmazie, 2009, vol. 342, # 12, p. 732 - 739
[29] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 20, p. 5965 - 5969
[30] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 9, p. 2942 - 2945
[31] ChemMedChem, 2010, vol. 5, # 3, p. 390 - 397
[32] European Journal of Medicinal Chemistry, 2010, vol. 45, # 12, p. 6020 - 6026
[33] European Journal of Medicinal Chemistry, 2011, vol. 46, # 11, p. 5276 - 5282
[34] Chemical Biology and Drug Design, 2011, vol. 78, # 2, p. 309 - 313
[35] European Journal of Medicinal Chemistry, 2013, vol. 64, p. 16 - 22
[36] European Journal of Medicinal Chemistry, 2014, vol. 82, p. 490 - 497
[37] Pharmazie, 1976, vol. 31, # 6, p. 351 - 354
[38] Journal fuer Praktische Chemie (Leipzig), 1973, vol. 315, p. 1169 - 1174
[39] Journal of Medicinal Chemistry, 2006, vol. 49, # 8, p. 2512 - 2525
[40] Synthetic Communications, 2007, vol. 37, # 2, p. 199 - 207
[41] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 20, p. 5368 - 5371
[42] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 3, p. 759 - 763
[43] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 2, p. 722 - 725
[44] European Journal of Medicinal Chemistry, 2011, vol. 46, # 7, p. 3135 - 3141
[45] European Journal of Medicinal Chemistry, 2011, vol. 46, # 9, p. 4391 - 4402
[46] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 17, p. 5363 - 5366
[47] European Journal of Medicinal Chemistry, 2014, vol. 71, p. 148 - 159
[48] European Journal of Medicinal Chemistry, 2014, vol. 74, p. 366 - 374
[49] Patent: CN105669573, 2016, A, . Location in patent: Paragraph 0056; 0062; 0063
[50] Patent: CN105524004, 2016, A, . Location in patent: Paragraph 0061; 0062
[51] Patent: CN105503753, 2016, A, . Location in patent: Paragraph 0034; 0055; 0061; 0062
[52] Chinese Journal of Chemistry, 2017, vol. 35, # 4, p. 483 - 496
[53] MedChemComm, 2017, vol. 8, # 8, p. 1631 - 1639
[54] Molecules, 2017, vol. 22, # 7,
[55] European Journal of Medicinal Chemistry, 2018, vol. 155, p. 579 - 589
  • 2
  • [ 1440-61-5 ]
  • [ 348-57-2 ]
  • [ 51336-94-8 ]
YieldReaction ConditionsOperation in experiment
96.5%
Stage #1: With magnesium In tetrahydrofuran at 30 - 35℃; for 2 h; Inert atmosphere
Stage #2: at 40℃; for 2 h;
Prepare a dry, clean 1000mL glass four-port bottle, equipped with a suitable mechanical stirrer, condensing tube and thermometer, check the airtightness before feeding, and add 96.5g to the reaction flask under N2 protection. 2,4-Difluorobromobenzene (0.5mol, 1.0eq),25.5 g (0.525 mol, 1.05 eq) of magnesium bar, 500 mL of tetrahydrofuran, stirring was started, the temperature of the reaction solution was raised to 30-35° C., and the reaction was stirred for 2 h. After the reaction was completed, the reaction solution was slowly added dropwise 163.6 g (1.0 mol). , 2.0 eq.) of 4-(2-chloroacetyl)morpholine (Compound 4) in tetrahydrofuran (163.6 g dissolved in 360 ml of tetrahydrofuran), the temperature controlled during the additionAt 40°C, after the addition is complete, continue incubation at 40°C for 2 hours. After the reaction was completed, the reaction system was quenched with 100 mL of saturated ammonium chloride solution. The reaction solution was concentrated under reduced pressure to remove most of the solvent, and then 500 mL of ethyl acetate was added for extraction. The separated ethyl acetate phase was washed with 300 mL of water and the organic phase was organic. It was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give 92.0 g of compound 5 (yield: 96.5percent).
Reference: [1] Patent: CN107746388, 2018, A, . Location in patent: Paragraph 0028; 0030; 0032; 0033; 0034; 0036; 0038; 0040
  • 3
  • [ 372-18-9 ]
  • [ 78-95-5 ]
  • [ 51336-94-8 ]
Reference: [1] Tetrahedron Letters, 2009, vol. 50, # 47, p. 6562 - 6566
  • 4
  • [ 364-83-0 ]
  • [ 51336-94-8 ]
Reference: [1] Advanced Synthesis and Catalysis, 2018, vol. 360, # 11, p. 2119 - 2124
  • 5
  • [ 51336-94-8 ]
  • [ 122263-03-0 ]
Reference: [1] Patent: US5661151, 1997, A,
[2] Patent: US5710154, 1998, A,
[3] Patent: US5698557, 1997, A,
[4] Patent: US5693626, 1997, A,
[5] Patent: US5703236, 1997, A,
[6] Patent: US5714490, 1998, A,
[7] Patent: US5116844, 1992, A,
[8] Patent: EP539938, 1993, A1,
  • 6
  • [ 51336-94-8 ]
  • [ 127-09-3 ]
  • [ 122263-03-0 ]
Reference: [1] Bulletin of the Chemical Society of Japan, 1996, vol. 69, # 9, p. 2625 - 2632
  • 7
  • [ 51336-94-8 ]
  • [ 782482-51-3 ]
Reference: [1] Journal of Organic Chemistry, 2005, vol. 70, # 9, p. 3592 - 3601
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 51336-94-8 ]

Fluorinated Building Blocks

Chemical Structure| 60468-36-2

[ 60468-36-2 ]

2-Chloro-2',5'-Difluoroacetophenone

Similarity: 0.98

Chemical Structure| 1979-36-8

[ 1979-36-8 ]

1-(2,5-Difluorophenyl)ethanone

Similarity: 0.82

Chemical Structure| 445-27-2

[ 445-27-2 ]

1-(2-Fluorophenyl)ethanone

Similarity: 0.82

Chemical Structure| 29427-48-3

[ 29427-48-3 ]

1-(2-Fluoro-4-methylphenyl)ethanone

Similarity: 0.81

Chemical Structure| 865664-05-7

[ 865664-05-7 ]

1-(2-Fluoro-3-methylphenyl)ethanone

Similarity: 0.81

Aryls

Chemical Structure| 60468-36-2

[ 60468-36-2 ]

2-Chloro-2',5'-Difluoroacetophenone

Similarity: 0.98

Chemical Structure| 1979-36-8

[ 1979-36-8 ]

1-(2,5-Difluorophenyl)ethanone

Similarity: 0.82

Chemical Structure| 445-27-2

[ 445-27-2 ]

1-(2-Fluorophenyl)ethanone

Similarity: 0.82

Chemical Structure| 29427-48-3

[ 29427-48-3 ]

1-(2-Fluoro-4-methylphenyl)ethanone

Similarity: 0.81

Chemical Structure| 865664-05-7

[ 865664-05-7 ]

1-(2-Fluoro-3-methylphenyl)ethanone

Similarity: 0.81

Chlorides

Chemical Structure| 60468-36-2

[ 60468-36-2 ]

2-Chloro-2',5'-Difluoroacetophenone

Similarity: 0.98

Chemical Structure| 347-93-3

[ 347-93-3 ]

3-Chloro-1-(4-fluorophenyl)propan-1-one

Similarity: 0.79

Chemical Structure| 3874-54-2

[ 3874-54-2 ]

4-Chloro-1-(4-fluorophenyl)butan-1-one

Similarity: 0.79

Chemical Structure| 541508-27-4

[ 541508-27-4 ]

1-(5-Chloro-2-fluorophenyl)ethanone

Similarity: 0.76

Chemical Structure| 1260018-63-0

[ 1260018-63-0 ]

4-Chloro-7-fluoro-2,3-dihydro-1H-inden-1-one

Similarity: 0.73

Ketones

Chemical Structure| 60468-36-2

[ 60468-36-2 ]

2-Chloro-2',5'-Difluoroacetophenone

Similarity: 0.98

Chemical Structure| 1979-36-8

[ 1979-36-8 ]

1-(2,5-Difluorophenyl)ethanone

Similarity: 0.82

Chemical Structure| 445-27-2

[ 445-27-2 ]

1-(2-Fluorophenyl)ethanone

Similarity: 0.82

Chemical Structure| 29427-48-3

[ 29427-48-3 ]

1-(2-Fluoro-4-methylphenyl)ethanone

Similarity: 0.81

Chemical Structure| 865664-05-7

[ 865664-05-7 ]

1-(2-Fluoro-3-methylphenyl)ethanone

Similarity: 0.81